Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.

Title

Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.

Creator

Uddin Zia; Maennle Diane; Russell Kimberly; Boltri John M

Publisher

The Journal of Family Practice

Date

2015
2015-07

Description

Varying combinations of 3 measurable factors determine a patient's risk of progressing toward multiple myeloma and influence monitoring decisions. This review–and accompanying algorithm–can guide your approach. For monoclonal gammopathy of undetermined significance (MGUS) patients at low risk, repeat serum protein electrophoresis (SPE) in 6 months. If no significant elevation of

Subject

Humans; Male; Middle Aged; Prevalence; Disease Progression; Risk Assessment; Blood Protein Electrophoresis; Connectin/analysis; Monoclonal Gammopathy of Undetermined Significance/*diagnosis/epidemiology/therapy

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

E5–E12

Issue

7

Volume

64

Citation

Uddin Zia; Maennle Diane; Russell Kimberly; Boltri John M, “Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.,” NEOMED Bibliography Database, accessed June 17, 2021, https://neomed.omeka.net/items/show/5675.

Social Bookmarking